NRF2 Cancer Research Results

NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
5471- AF,    Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice
- vitro+vivo, Melanoma, B16-F10
TrxR1↓, AntiTum↑, ROS↑, NRF2↑, TumCD↑,
5470- AF,    Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin
- Review, Var, NA
TrxR↓, other↝, IL6↑, IL8↑, NK cell⇅, COX2/PTGS2↓, NOS2↓, NRF2↑, Prx↑, Half-Life↑, Dose↝, ROS↑, NF-kB↓,
5238- AgNPs,    β-Sitosterol-assisted silver nanoparticles activates Nrf2 and triggers mitochondrial apoptosis via oxidative stress in human hepatocellular cancer cell line
- in-vitro, HCC, HepG2
TumCP↓, ROS↑, NRF2↑, BAX↑, P53↑, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓,
4561- AgNPs,  VitC,    Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts
- in-vitro, CRC, HCT116 - in-vitro, Nor, HEK293
NRF2↑, TumCCA↑, ROS↑, selectivity↑, *AntiViral↑, *toxicity↝, ETC↓, MMP↓, DNAdam↑, Apoptosis↑, lipid-P↑, other↝, UPR↑, *GRP78/BiP↑, *p‑PERK↑, *cl‑eIF2α↑, *CHOP/DDIT3↑, *JNK↑, Hif1a↓, AntiCan↑, *toxicity↓, eff↑,
372- AgNPs,    Investigating oxidative stress and inflammatory responses elicited by silver nanoparticles using high-throughput reporter genes in HepG2 cells: effect of size, surface coating, and intracellular uptake
- in-vitro, Hepat, HepG2
NRF2↑, GSH↓,
236- AL,    Allicin: Chemistry and Biological Properties
- Analysis, NA, NA
GSH↓, Bacteria↓, LDL↓, ROS↑, NRF2↑, cognitive↑, memory↑, BP↓, RNS↓,
278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, NA, NA
ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, eff↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,
1159- And,    Andrographolide, an Anti-Inflammatory Multitarget Drug: All Roads Lead to Cellular Metabolism
- Review, NA, NA
NRF2↑, COX2/PTGS2↓, IL6↓, IL8↓, IL1↓, iNOS↓, MPO↓, TNF-α↓, VEGF↓, Hif1a↓, p‑AMPK↑,
3387- ART/DHA,    Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment
- Review, Var, NA
BioAv↓, lipid-P↑, Ferroptosis↑, Iron↑, GPx4↓, GSH↓, P53↑, ER Stress↑, PERK↑, ATF4↑, GRP78/BiP↑, CHOP/DDIT3↑, ROS↑, NRF2↑,
3388- ART/DHA,    Keap1 Cystenine 151 as a Potential Target for Artemisitene-Induced Nrf2 Activation
- in-vitro, Lung, A549 - in-vitro, Nor, GP-293 - in-vitro, BC, MDA-MB-231
NRF2↑, ROS∅,
3389- ART/DHA,    Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers
- Review, Var, NA
GSH↓, ROS↑, NRF2↑, eff↑,
567- ART/DHA,    An Untargeted Proteomics and Systems-based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells
- in-vitro, Lung, BEAS-2B
NRF2↑, AP-1↑, NFAT↑,
1076- ART/DHA,    The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer
- Review, NA, NA
Ferroptosis↑, ROS↑, ER Stress↑, i-Iron↓, TumAuto↑, AMPK↑, mTOR↑, P70S6K↑, Fenton↑, lipid-P↑, ROS↑, ChemoSen↑, NRF2↑, NRF2↓,
3173- Ash,    Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma
- in-vitro, neuroblastoma, NA
GPx4↓, HO-1↑, lipid-P↑, Keap1↓, NRF2↑, Ferroptosis↑,
3160- Ash,    Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal
- Review, Var, NA
TumCCA↑, H3↑, P21↑, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDC2↓, CHK1↓, Chk2↓, p38↑, MAPK↑, E6↓, E7↓, P53↑, Akt↓, FOXO3↑, ROS↑, γH2AX↑, MMP↓, mitResp↓, eff↑, TumCD↑, Mcl-1↓, ER Stress↑, ATF4↑, ATF3↑, CHOP/DDIT3↑, NOTCH↓, NF-kB↓, Bcl-2↓, STAT3↓, CDK1↓, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, Cyt‑c↑, eff↑, CDK4↓, p‑RB1↓, PARP↑, cl‑Casp3↑, cl‑Casp9↑, NRF2↑, ER-α36↓, LDHA↓, lipid-P↑, AP-1↓, COX2/PTGS2↓, RenoP↑, PDGFR-BB↓, SIRT3↑, MMP2↓, MMP9↓, NADPH↑, NQO1↑, GSR↑, HO-1↑, *SOD2↑, *Prx↑, *Casp3?, eff↑, Snail↓, Slug↓, Vim↓, CSCs↓, HEY1↓, MMPs↓, VEGF↓, uPA↓, *toxicity↓, CDK2↓, CDK4↓, HSP90↓,
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoPv↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,
4804- ASTX,    Astaxanthin in cancer therapy and prevention (Review)
- Review, Var, NA - Review, AD, NA
*antiOx↑, *Inflam↓, ChemoSen⇅, chemoP↑, BioAv↑, TumCP↑, ROS⇅, Apoptosis↑, PI3K↑, Akt↑, GSK‐3β↑, NRF2↑, AntiCan↑, *neuroP↑, eff↑, AntiTum↑,
1385- BBR,  5-FU,    Low-Dose Berberine Attenuates the Anti-Breast Cancer Activity of Chemotherapeutic Agents via Induction of Autophagy and Antioxidation
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
eff↓, ROS↑, TumCP↑, NRF2↑, ChemoSen↓,
2757- BetA,    Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways
- in-vitro, GBM, U251
tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, p‑PI3K↓, p‑Akt↓, Ferroptosis↑, HO-1↑, NRF2↑,
5686- BJ,  BRU,    A review of Brucea javanica: metabolites, pharmacology and clinical application
- Review, Var, NA
AntiTum↑, other↝, ChemoSen↑, QoL↑, chemoP↑, *Inflam↓, NF-kB↓, TumCP↓, TumCI↓, TumMeta↓, Hif1a↓, NRF2↓, STAT3↓, COX2/PTGS2↓, Casp3↑, Casp9↑, ROS↑, EGFR↓, NRF2↑,
3511- Bor,    Boron
- Review, NA, NA
*memory↑, *motorD↑, *neuroP↑, Ca+2↓, ATF4↑, NRF2↑, *Inflam↓, *ROS↓,
3513- Bor,    Boric Acid Activation of eIF2α and Nrf2 Is PERK Dependent: a Mechanism that Explains How Boron Prevents DNA Damage and Enhances Antioxidant Status
- in-vitro, Pca, DU145 - in-vitro, Nor, MEF
NRF2↑, selectivity↑, NQO1↑, GCLC↑, HO-1↑, TumCP↓,
726- Bor,    Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open
- Review, NA, NA
NAD↝, SAM-e↝, PSA↓, IGF-1↓, Cyc↓, P21↓, p‑MEK↓, p‑ERK↓, ROS↑, SOD↓, Catalase↓, MDA↑, GSH↓, IL1↓, IL6↓, TNF-α↓, BRAF↝, MAPK↝, PTEN↝, PI3K/Akt↝, eIF2α↑, ATF4↑, ATF6↑, NRF2↑, BAX↑, BID↑, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓,
5847- CAP,    An updated review on molecular mechanisms underlying the anticancer effects of capsaicin
- in-vitro, Liver, HepG2
HO-1↑, ROS↑, NRF2↑, *lipid-P↓, *SOD↑, *Catalase↑, *GPx↑, *GSR↑, *PGE2↓, *COX2/PTGS2↓, *iNOS↓, TumCP↓, TumCCA↑, cycE/CCNE↓, CDK4↓, MMP↓, P53↑, P21↑, BAX↑, SIRT1↑, angioG↓, P-gp/ABCB1↓, ChemoSen↑,
2392- Cela,    The role of natural products targeting macrophage polarization in sepsis-induced lung injury
- Review, Sepsis, NA
TNF-α↓, IL1β↓, IL6↓, Warburg↓, PKM2↓, NRF2↑, HO-1↑, NF-kB↓, iNOS↓, M1↓,
6005- CGA,  Rad,    Chlorogenic Acid, the Main Antioxidant in Coffee, Reduces Radiation-Induced Apoptosis and DNA Damage via NF-E2-Related Factor 2 (Nrf2) Activation in Hepatocellular Carcinoma
- in-vitro, HCC, HUH7
RadioS↓, ROS↓, NRF2↑,
6002- CGA,    Chlorogenic Acid: A Systematic Review on the Biological Functions, Mechanistic Actions, and Therapeutic Potentials
- Review, Var, NA - Review, Diabetic, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *Inflam↓, *antiOx↑, *cardioP↑, *NRF2↑, *AMPK↑, *SOD↑, *Catalase↑, *GSH↑, *GPx↑, *ROS↓, *TNF-α↓, *IL6↓, *NF-kB↓, *COX2/PTGS2↓, *glucose↓, *TRPC1↓, *Ca+2↓, *HO-1↑, *NF-kB↓, *PPARα↝, *Hif1a↓, *JNK↓, *BP↓, *AntiDiabetic↑, *hepatoP↑, *TLR4↓, *NRF2↑, *Casp↓, *neuroP↑, *Aβ↓, *LDH↓, *MDA↓, *memory↑, *AChE↓, *eff↑, EMT↝, N-cadherin↓, E-cadherin↑, TumCCA↑, ROS↑, p‑P53↑, HO-1↑, NRF2↑, ChemoSen↑, mtDam↑, Casp3↑, Casp9↑, PARP↑, Bax:Bcl2↑, TumCG↓, cycD1/CCND1↓, cMyc↓, CDK2↓, mitResp↓, Glycolysis↓, Hif1a↓, PCNA↓, p‑GSK‐3β↓, VEGF↓, PI3K↓, Akt↓, mTOR↓, OS↑,
6007- CGA,    A Comprehensive View on the Impact of Chlorogenic Acids on Colorectal Cancer
- Review, CRC, NA
antiOx↑, TumCCA↑, Apoptosis↑, Wnt↝, PI3K↝, MAPK↝, ROS↓, BioAv↝, P53↑, P21↑, CDK1↑, Ki-67↓, Ca+2↑, p‑Akt↓, mTOR↓, GSH↑, NRF2↑, HO-1↑, COX2/PTGS2↓, TNF-α↓, IL1β↓, IL6↓,
7164- CHA,    Chaetocin induces apoptosis in human melanoma cells through the generation of reactive oxygen species and the intrinsic mitochondrial pathway, and exerts its anti-tumor activity in vivo
- vitro+vivo, Melanoma, A375
TumCP↓, Apoptosis↑, ROS↑, eff↓, MMP↓, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑Casp9↑, Bcl-2↓, TumCG↓, PCNA↓, tumCV↓, NRF2↑, SOD2↑, Catalase↑, NRF2↓, SOD2↓, Catalase↓, TrxR↓,
6314- Cro,    Crocin promotes ferroptosis in gastric cancer via the Nrf2/GGTLC2 pathway
- in-vitro, GC, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↓, antiOx↓, Ferroptosis↑, NRF2↑, P53↑, TumCCA↑, ChemoSen↑, EMT↓, Hif1a↓, ROS↑,
6300- Cro,    Interaction of saffron and its constituents with Nrf2 signaling pathway: A review
- Review, Nor, NA - Review, Arthritis, NA
*antiOx↑, *Inflam↓, *AntiTum↑, *hepatoP↑, *cardioP↑, *neuroP↑, *NRF2↑, *NF-kB↓, *iNOS↓, *COX2/PTGS2↓, *IL6↓, *IL10↓, *IL1β↓, *TNF-α↓, *HO-1↑, ROS↑, NQO1↑, NRF2↑, HO-1↑, NQO2↑, LDHA↓, ATP↓, *hepatoP↑, *SOD↑, *Catalase↑, *GPx↑, *NRF2↑, *ROS↓, *cardioP↑, *ER Stress↓, *GRP78/BiP↓, *CHOP/DDIT3↓, *Apoptosis↓, *miR-34a↓, *SIRT1↑, chemoP↑,
6297- Cro,    Crocetin Exerts Its Anti-inflammatory Property in LPS-Induced RAW264.7 Cells Potentially via Modulation on the Crosstalk between MEK1/JNK/NF-κB/iNOS Pathway and Nrf2/HO-1 Pathway
- in-vitro, Nor, RAW264.7
*NO↓, *iNOS↓, *Inflam↓, *MEK↓, JNK↓, NF-kB↓, NRF2↑, HO-1↑, hepatoP↑, neuroP↑,
7412- CS,  Chemo,    Artichoke Polyphenols Sensitize Human Breast Cancer Cells to Chemotherapeutic Drugs via a ROS-Mediated Downregulation of Flap Endonuclease 1
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Apoptosis↑, ROS↑, TumCP↓, DNAdam↑, FEN1↓, ChemoSen↑, NRF2↑,
6223- CUR,    Curcumin Rewires the Tumor Metabolic Landscape: Mechanisms and Clinical Prospects
- Review, Var, NA
Ferroptosis↑, GutMicro↑, Akt↓, mTOR↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, STAT3↓, TumCP↓, TumCI↓, TumMeta↓, AMPK↑, P53↑, NRF2↑, TumCCA↑, Apoptosis↑, Casp↑, GPx4↓, DNMTs↓, HDAC↓, VEGF↓, Imm↑, NK cell↑, Warburg↓, Hif1a↓, HK2↓, PKM2↓, LDHA↓, GLUT1↓, MCT1↓, AMPK↑, FASN↓, SCD1↓, GLS↓, Apoptosis↑, ETC↓, MMP↓, ROS↑, lipid-P↑, ChemoSen↑, PDK1 / PDPK1↓, Beclin-1/ATG6↓, ATP↓, Glycolysis↓, GlucoseCon↓, lactateProd↑, MMPs↓, GSH↓, G6PD↓, OXPHOS↓, SREBP2↓, COX2/PTGS2↓, AP-1↓, NADH↓, NRF2↑, HO-1↑, Iron↑, MDA↑, *ROS↓, *Inflam↓,
405- CUR,  5-FU,    Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis
- vitro+vivo, CRC, HCT116
Apoptosis↑, TumCMig↓, NRF2↑, ROS↑, MET↑, miR-34a↑,
410- CUR,    Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS
- vitro+vivo, GC, AGS - vitro+vivo, GC, HGC27
ROS↑, NRF2↑, eff↓, eff↑,
414- CUR,    Transcriptome Investigation and In Vitro Verification of Curcumin-Induced HO-1 as a Feature of Ferroptosis in Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Ferroptosis↑, Iron↑, ROS↑, lipid-P↑, MDA↑, GSH↓, HO-1↑, NRF2↑, GPx↓, ROS↑, Iron↑, GPx4↓, HSP70/HSPA5↑, ATFs↑, CHOP/DDIT3↑, MDA↑, FTL↑, FTH1↑, BACH1↑, REL↑, USF1↑, NFE2L2↑,
13- CUR,    Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action
- Review, BC, NA
P53↑, DR5↑, JNK↑, NRF2↑, PPARγ↑, HER2/EBBR2↓, IR↓, ER(estro)↓, Fas↑, PDGF↓, TGF-β↓, FGF↓, EGFR↓, JAK↓, PAK↓, MAPK↓, ATPase↓, COX2/PTGS2↓, MMPs↓, IL1↓, IL2↓, IL5↓, IL6↓, IL8↓, IL12↓, IL18↓, NF-kB↓, NOTCH1↓, STAT1↓, STAT4↓, STAT5↓, STAT3↓,
7451- CYN,    Inhibitory effects of cynaropicrin on human melanoma progression by targeting MAPK, NF‐κB, and Nrf‐2 signaling pathways in vitro
- in-vitro, Melanoma, A375
TumCP↓, Casp3↑, Apoptosis↑, TumCMig↓, TumCI↓, ERK↓, NF-kB↓, ROS↓, HO-1↑, NRF2↑, Bcl-2↓, NF-kB↓, other↝,
3220- EGCG,    Dual Roles of Nrf2 in Cancer
- in-vitro, Lung, A549
NRF2↑, eff↓,
3219- EGCG,    Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling
- in-vitro, Lung, A549
ROS↑, RNS↓, MMP↓, NRF2↑, Keap1↓,
3215- EGCG,    Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
TumCP↓, Ki-67↓, GPx4↓, ACSL4↑, Iron↑, MDA↑, ROS↑, Ferroptosis↑, eff↑, NRF2↑, HO-1↑,
3216- EGCG,    Epigallocatechin-3-gallate suppresses hemin-aggravated colon carcinogenesis through Nrf2-inhibited mitochondrial reactive oxygen species accumulation
- NA, Colon, Caco-2
NRF2↑, TumCP↓, mt-ROS↓, Keap1↓,
3213- EGCG,  Rad,    Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy
- in-vitro, CRC, HCT116
RadioS↑, TumCP↓, NRF2↑,
20- EGCG,    Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer
- in-vivo, Liver, NA - in-vivo, Tong, NA
HH↓, Gli1↓, Smo↓, TNF-α↓, COX2/PTGS2↓, *antiOx↑, Hif1a↓, NF-kB↓, VEGF↓, STAT3↓, Bcl-2↓, P53↑, Akt↓, p‑Akt↓, p‑mTOR↓, EGFR↓, AP-1↓, BAX↑, ROS↑, Casp3↑, Apoptosis↑, NRF2↑, *H2O2↓, *NO↓, *SOD↑, *Catalase↑, *GPx↑, *ROS↓,
5228- EMD,    Evaluating anticancer activity of emodin by enhancing antioxidant activities and affecting PKC/ADAMTS4 pathway in thioacetamide-induced hepatocellular carcinoma in rats
- in-vivo, HCC, NA
OS↑, PKCδ↓, ERK5↓, MMP3↓, VEGF↓, NRF2↑, HO-1↑, MDA↓, AFP↓,
6356- Eug,  Cin,    Investigating the Molecular Mechanisms of the Anticancer Effects of Eugenol and Cinnamaldehyde Against Colorectal Cancer (CRC) Cells In Vitro
- in-vitro, CRC, SW-620 - in-vitro, CRC, Caco-2 - in-vitro, Nor, NCM460
P21↑, ChemoSen↑, Casp3↑, IL4↓, IL8↓, ROS↑, NRF2↑, HO-1↑, EMT↓,
2858- FIS,    Fisetin inhibits cell migration via inducing HO-1 and reducing MMPs expression in breast cancer cell lines
- in-vitro, BC, 4T1
HO-1↑, NRF2↑, MMP2↓, MMP9↓,
2861- FIS,    The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress
- Review, Nor, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *ROS↓, *neuroP↑, *NO↑, BioAv↝, *BBB↑, *toxicity↑, *eff↑, *GSH↑, *SOD↑, *Aβ↓, *12LOX↓, *COX2/PTGS2↓, *Catalase↑, *Inflam↓, *TNF-α↓, *IL6↑, *lipid-P↓, NF-kB↓, IL1β↓, NRF2↑, HO-1↑, GSTs↑, cognitive↑, *BDNF↑,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1/ATG6↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2/KDR/Flk1↓, IAP2/BIRC3↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,

Showing Research Papers: 1 to 50 of 119
Page 1 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 119

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

p‑AMT/GCST/T-protein↑, 1,   FEN1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 3,   antiOx↑, 6,   ARE↑, 1,   ATF3↑, 2,   Catalase↓, 2,   Catalase↑, 9,   Fenton↑, 1,   Ferroptosis↑, 11,   frataxin↑, 1,   GCLC↑, 1,   GCLM↑, 2,   GPx↓, 1,   GPx↑, 6,   GPx1⇅, 1,   GPx4↓, 7,   GSH↓, 13,   GSH↑, 10,   GSH/GSSG↓, 2,   GSR↑, 2,   GSS↑, 1,   GSSG↑, 3,   GSTA1↑, 1,   GSTP1/GSTπ↑, 1,   GSTs↑, 2,   H2O2↓, 2,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 40,   Iron↑, 6,   i-Iron↓, 1,   i-Iron↑, 1,   Keap1↓, 5,   Keap1↝, 1,   lipid-P↓, 1,   lipid-P↑, 9,   MDA↓, 3,   MDA↑, 7,   MPO↓, 2,   NADH↓, 1,   NAF1↓, 3,   NFE2L2↑, 1,   NQO1↑, 12,   NRF2↓, 5,   NRF2↑, 119,   NRF2↝, 1,   p‑NRF2↑, 2,   OXPHOS↓, 2,   mt-OXPHOS↓, 1,   Prx↑, 1,   Prx4↑, 1,   RNS↓, 2,   ROS?, 2,   ROS↓, 17,   ROS↑, 60,   ROS⇅, 1,   ROS↝, 1,   ROS∅, 1,   mt-ROS↓, 1,   mt-ROS↑, 2,   SAM-e↝, 1,   SIRT3↑, 2,   SOD↓, 1,   SOD↑, 12,   SOD1↑, 1,   SOD2↓, 1,   SOD2↑, 3,   Trx↑, 1,   TrxR↓, 4,   TrxR1↓, 1,   xCT/SLC7A11↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↑, 1,   FTL↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 4,   ATP↑, 1,   CDC2↓, 4,   CDC25↓, 2,   EGF↓, 1,   ETC↓, 2,   FGFR1↓, 1,   p‑MEK↓, 1,   mitResp↓, 2,   MMP↓, 15,   mtDam↑, 2,   Raf↓, 1,   c-Raf↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 1,   ACSL4↑, 1,   AKT1↓, 1,   AMPK↑, 7,   p‑AMPK↑, 1,   ATG7↑, 1,   CAIX/CA9↓, 1,   cMyc↓, 7,   p‑cMyc↑, 1,   FASN↓, 2,   G6PD↓, 1,   GLS↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 8,   HK2↓, 5,   IR↓, 1,   lactateProd↓, 2,   lactateProd↑, 1,   LDH↓, 1,   LDH↑, 1,   LDHA↓, 3,   LDL↓, 1,   NAD↝, 1,   NADPH↓, 1,   NADPH↑, 3,   PCK1↓, 1,   PDK1 / PDPK1↓, 1,   PI3K/Akt↓, 1,   PI3K/Akt↝, 1,   PKM2↓, 2,   PPARγ↑, 3,   PPP↑, 1,   SCD1↓, 1,   SIRT1↑, 3,   SREBP2↓, 1,   Warburg↓, 4,  

Cell Death(tgid=5) ⓘ

AhR↓, 1,   Akt↓, 15,   Akt↑, 1,   p‑Akt↓, 9,   Apoptosis↓, 2,   Apoptosis↑, 29,   Bak↑, 1,   BAX↑, 19,   Bax:Bcl2↑, 5,   Bcl-2↓, 18,   Bcl-xL↓, 4,   BID↑, 3,   BIM↑, 2,   Casp↑, 4,   Casp12?, 1,   Casp3↓, 2,   Casp3↑, 23,   cl‑Casp3↑, 5,   Casp7↑, 3,   Casp8↑, 4,   Casp8∅, 2,   cl‑Casp8↑, 1,   Casp9↑, 18,   cl‑Casp9↑, 4,   Chk2↓, 1,   Chk2↑, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 14,   Diablo↑, 3,   DR4↑, 1,   DR5↑, 9,   Fas↑, 2,   FasL↑, 1,   Ferroptosis↑, 11,   HEY1↓, 1,   hTERT/TERT↓, 4,   IAP1↓, 2,   IAP1↑, 1,   IAP2/BIRC3↓, 2,   ICAD↑, 1,   iNOS↓, 7,   JNK↓, 1,   JNK↑, 5,   MAPK↓, 6,   MAPK↑, 6,   MAPK↝, 2,   Mcl-1↓, 4,   Mcl-1↑, 1,   MCT1↓, 1,   MDM2↓, 2,   NICD↓, 1,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 5,   p38↓, 1,   p38↑, 3,   p‑p38↓, 1,   PUMA↑, 1,   survivin↓, 12,   Telomerase↓, 2,   TRAIL↑, 1,   TRAILR↑, 1,   TumCD↑, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

AMPKα↑, 1,   EF-1α↓, 1,   HER2/EBBR2↓, 6,   p‑HER2/EBBR2↓, 1,   p70S6↓, 1,   PAK↓, 1,   SOX9↓, 1,   Sp1/3/4↓, 4,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↑, 1,   H3↑, 2,   p‑H3↓, 1,   ac‑H3↑, 1,   H4↑, 1,   ac‑H4↑, 1,   HATs↓, 1,   HATs↑, 1,   miR-21↑, 1,   miR-30a-5p↑, 1,   other↑, 1,   other⇅, 1,   other↝, 5,   p‑pRB↓, 1,   TET3↑, 1,   tumCV↓, 11,   USF1↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 2,   ATFs↑, 1,   CHOP/DDIT3↑, 10,   cl‑CHOP/DDIT3↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 13,   GRP78/BiP↑, 4,   HSP27↑, 1,   HSP27↝, 1,   HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 2,   HSP70/HSPA5↝, 1,   HSP90↓, 2,   ac‑HSP90↑, 1,   NQO2↑, 1,   PERK↑, 2,   UPR↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 2,   Beclin-1/ATG6↓, 1,   Beclin-1/ATG6↑, 2,   LC3B-II↑, 2,   LC3II↑, 1,   LC3s↑, 1,   SESN2↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   CHK1↓, 1,   CHK1↑, 1,   DNAdam↓, 2,   DNAdam↑, 9,   DNMT1↓, 4,   DNMT3A↓, 4,   DNMTs↓, 6,   MGMT↓, 1,   P53?, 1,   P53↑, 26,   p‑P53↑, 1,   PARP↓, 1,   PARP↑, 2,   cl‑PARP↓, 2,   cl‑PARP↑, 13,   cl‑PARP1↑, 1,   PCNA↓, 7,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 3,   CDK1↑, 3,   CDK2↓, 11,   CDK2↑, 2,   CDK4↓, 13,   Cyc↓, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 11,   cycD1/CCND1↑, 1,   cycE/CCNE↓, 4,   cycE/CCNE↑, 1,   p19↑, 1,   P21?, 1,   P21↓, 1,   P21↑, 16,   RB1↓, 1,   p‑RB1↓, 4,   TumCCA?, 1,   TumCCA↓, 2,   TumCCA↑, 29,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   ALDH1A1↓, 1,   BRAF↝, 1,   CD133↓, 3,   CD44↓, 4,   cFos↓, 1,   cMET↓, 1,   cMYB↓, 1,   CSCs↓, 9,   EMT↓, 13,   EMT↝, 1,   ERK↓, 7,   ERK↑, 3,   p‑ERK↓, 1,   ERK5↓, 1,   FGF↓, 2,   FOXO↑, 1,   FOXO3↓, 1,   FOXO3↑, 2,   p‑FOXO3↓, 1,   Gli1↓, 2,   GSK‐3β↓, 3,   GSK‐3β↑, 3,   p‑GSK‐3β↓, 2,   HDAC↓, 15,   HDAC↑, 1,   HDAC1↓, 1,   HDAC2↓, 2,   HDAC3↓, 1,   HDAC8↓, 1,   HH↓, 1,   IGF-1↓, 3,   IGFBP3↑, 1,   miR-34a↑, 2,   mTOR↓, 14,   mTOR↑, 1,   p‑mTOR↓, 3,   mTORC1↓, 2,   mTORC2↓, 1,   Nanog↓, 3,   Nestin↓, 1,   NOTCH↓, 3,   NOTCH1↓, 4,   NOTCH3↓, 2,   OCT4↓, 3,   P70S6K↓, 1,   P70S6K↑, 1,   p‑P70S6K↓, 1,   PI3K↓, 11,   PI3K↑, 2,   PI3K↝, 1,   p‑PI3K↓, 2,   PTEN↑, 4,   PTEN↝, 1,   RAS↓, 4,   Shh↓, 2,   Smo↓, 2,   SOX2↓, 2,   STAT1↓, 2,   STAT3↓, 12,   p‑STAT3↓, 1,   STAT4↓, 1,   STAT5↓, 1,   STAT6↓, 1,   TAZ↓, 1,   TOP2↓, 1,   TumCG↓, 12,   Wnt↓, 8,   Wnt↝, 1,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   AP-1↓, 4,   AP-1↑, 1,   ATPase↓, 1,   BACH1↑, 1,   Ca+2↓, 1,   Ca+2↑, 4,   E-cadherin↑, 5,   ER-α36↓, 2,   FAK↓, 3,   ITGB1↓, 1,   ITGB3↓, 1,   Ki-67↓, 4,   MET↑, 2,   miR-155↓, 1,   miR-200c↑, 1,   MMP1↓, 2,   MMP13↓, 1,   MMP2↓, 12,   MMP3↓, 3,   MMP7↓, 4,   MMP9↓, 14,   MMPs↓, 10,   N-cadherin↓, 5,   NFAT↑, 1,   PDGF↓, 2,   PKCδ↓, 3,   PKCδ↑, 1,   PRNP↑, 1,   Rho↓, 1,   Slug↓, 2,   Smad1↑, 1,   Snail↓, 4,   SOX4↓, 1,   SOX4↑, 1,   TET1↓, 1,   TET1↑, 2,   TGF-β↓, 2,   TIMP1↑, 1,   TIMP2↑, 1,   TSP-1↑, 1,   TumCI↓, 14,   TumCMig↓, 10,   TumCP↓, 28,   TumCP↑, 2,   TumMeta↓, 9,   Twist↓, 2,   uPA↓, 5,   uPAR↓, 1,   Vim↓, 3,   Zeb1↓, 3,   β-catenin/ZEB1↓, 7,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 16,   ATF4↑, 5,   ATF4↝, 1,   EGFR↓, 10,   HIF-1↓, 1,   Hif1a↓, 19,   NO↓, 2,   PDGFR-BB↓, 1,   REL↑, 1,   VEGF↓, 21,   VEGFR2/KDR/Flk1↓, 4,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 2,   P-gp/ABCB1↓, 4,   P-gp/ABCB1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 23,   CRP↓, 1,   CXCR4↓, 2,   ICAM-1↓, 1,   IFN-γ↓, 2,   IFN-γ↑, 1,   IKKα↓, 2,   IL1↓, 3,   IL10↓, 1,   IL10↑, 1,   IL12↓, 1,   IL18↓, 1,   IL1β↓, 6,   IL2↓, 1,   IL2↑, 1,   IL4↓, 1,   IL4↑, 1,   IL5↓, 1,   IL6↓, 14,   IL6↑, 1,   IL8↓, 5,   IL8↑, 1,   Imm↑, 1,   Inflam↓, 7,   JAK↓, 1,   JAK1↓, 2,   JAK2↓, 1,   M1↓, 1,   NF-kB↓, 36,   p‑NF-kB↑, 1,   NK cell↑, 2,   NK cell⇅, 1,   p65↓, 1,   PD-L1↓, 3,   PGE2↓, 4,   PSA↓, 3,   PSA∅, 1,   TLR4↓, 1,   TNF-α↓, 14,  

Cellular Microenvironment(tgid=17) ⓘ

NOX↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 2,   AChE↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 3,   CDK6↓, 4,   COMT↑, 1,   ER(estro)↓, 1,   GR↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 9,   BioAv↑, 8,   BioAv↝, 4,   BioEnh?, 1,   BioEnh↑, 1,   chemoR↓, 1,   ChemoSen↓, 2,   ChemoSen↑, 28,   ChemoSen⇅, 1,   Dose↝, 9,   eff↓, 12,   eff↑, 32,   eff↝, 2,   Half-Life↓, 2,   Half-Life↑, 1,   Half-Life↝, 2,   MDR1↓, 2,   MRP1/ABCC1↓, 1,   P450↓, 1,   RadioS↓, 1,   RadioS↑, 9,   selectivity↑, 16,   TET2↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 1,   AR↓, 3,   BP↓, 1,   BRAF↝, 1,   CRP↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 10,   GutMicro↑, 1,   GutMicro↝, 1,   HER2/EBBR2↓, 6,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 4,   IL6↓, 14,   IL6↑, 1,   Ki-67↓, 4,   LDH↓, 1,   LDH↑, 1,   NOS2↓, 1,   PD-L1↓, 3,   PSA↓, 3,   PSA∅, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 8,   AntiTum↑, 5,   cardioP↑, 2,   CardioT↓, 1,   chemoP↑, 5,   chemoPv↑, 3,   ChemoSideEff↓, 2,   cognitive↑, 3,   hepatoP↑, 3,   memory↑, 2,   neuroP↑, 9,   OS↑, 5,   QoL↑, 2,   RenoP↑, 2,   Risk↓, 2,   toxicity↓, 1,   toxicity↑, 1,   TumW↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 529

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 12,   Catalase↑, 8,   GPx↑, 6,   GSH↑, 5,   GSR↑, 1,   GSTA1↓, 1,   GSTs↑, 1,   H2O2↓, 2,   HO-1↑, 7,   Keap1↓, 1,   lipid-P↓, 5,   MDA↓, 1,   NQO1↑, 1,   NRF2↓, 2,   NRF2↑, 6,   Prx↑, 1,   ROS↓, 16,   ROS↑, 1,   ROS∅, 1,   SOD↑, 7,   SOD2↑, 1,   VitC↑, 1,   VitE↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MEK↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   AMPK↑, 2,   glucose↓, 1,   LDH↓, 1,   PPARα↝, 1,   p‑PPARγ↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Casp↓, 1,   Casp3?, 1,   Cyt‑c↓, 1,   IAP1↓, 1,   iNOS↓, 4,   JNK↓, 1,   JNK↑, 1,   p‑JNK↓, 1,   p38↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   CHOP/DDIT3↑, 1,   cl‑eIF2α↑, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,   GRP78/BiP↑, 1,   HSP27↓, 1,   p‑PERK↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

HDAC↓, 1,   HDAC3↓, 1,   miR-34a↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   Ca+2↓, 1,   Ki-67↓, 1,   TRPC1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   NO↓, 2,   NO↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 6,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 3,   IL6↓, 4,   IL6↑, 1,   IL8↓, 1,   Inflam↓, 11,   NF-kB↓, 3,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 5,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BDNF↑, 1,   GABA↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

GR↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv?, 1,   BioAv↓, 3,   BioAv↑, 2,   BioAv↝, 2,   Dose↑, 1,   Dose↝, 1,   eff↑, 2,   Half-Life↝, 2,   Half-Life∅, 1,   P450↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BG↓, 1,   BP↓, 1,   GutMicro↑, 1,   IL6↓, 4,   IL6↑, 1,   Ki-67↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 2,   AntiCan↑, 1,   AntiDiabetic↑, 1,   AntiTum↑, 1,   cardioP↑, 5,   chemoPv↑, 1,   hepatoP↑, 6,   memory↑, 2,   motorD↓, 1,   motorD↑, 1,   neuroP↓, 1,   neuroP↑, 9,   toxicity↓, 7,   toxicity↑, 1,   toxicity↝, 1,   toxicity∅, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,  
Total Targets: 114

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
16 Sulforaphane (mainly Broccoli)
8 Resveratrol
7 Fisetin
6 EGCG (Epigallocatechin Gallate)
6 Thymoquinone
5 Artemisinin
5 Curcumin
5 Piperlongumine
4 Silver-NanoParticles
3 Ashwagandha(Withaferin A)
3 Boron
3 Chlorogenic acid
3 Crocetin
3 Lycopene
3 Phenethyl isothiocyanate
3 Quercetin
3 Silymarin (Milk Thistle) silibinin
2 Auranofin
2 Vitamin C (Ascorbic Acid)
2 5-fluorouracil
2 Radiotherapy/Radiation
2 Chemotherapy
2 Luteolin
2 xanthohumol
2 Rosmarinic acid
1 Allicin (mainly Garlic)
1 Alpha-Lipoic-Acid
1 Andrographis
1 Astaxanthin
1 Berberine
1 Betulinic acid
1 Brucea javanica
1 brusatol
1 Capsaicin
1 Celastrol
1 chaetocin
1 Cynara scolymus/Globe Artichoke/Artichoke Extract
1 Cynaropicrin
1 Emodin
1 Eugenol
1 Cinnamon
1 Gallic acid
1 Hydroxycinnamic-acid
1 Honokiol
1 iodine
1 Isoliquiritigenin
1 Kaempferol
1 Lapatinib
1 Lutein
1 Methyl salicylate / Sweet Birch oil
1 Aspirin
1 Parthenolide
1 Pterostilbene
1 Selenium
1 acetazolamide
1 Spermidine
1 erastin
1 Selenite (Sodium)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:226  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page